Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Brain spectroscopy reveals that N-acetylaspartate is associated to peripheral sensorimotor neuropathy in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality and complications after treatment of acute diabetic Charcot foot

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Glenn M Chertow
  • Gerald B Appel
  • Geoffrey A Block
  • Melanie P Chin
  • Daniel W Coyne
  • Angie Goldsberry
  • Kamyar Kalantar-Zadeh
  • Colin J Meyer
  • Mark E Molitch
  • Pablo E Pergola
  • Philip Raskin
  • Arnold L Silva
  • Bruce Spinowitz
  • Stuart M Sprague
  • Peter Rossing
View graph of relations

AIMS: Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.

METHODS: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30 mL/min/1.73 m2) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo.

RESULTS: BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -5.3 kg; p < 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control.

CONCLUSIONS: Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.

Original languageEnglish
JournalJournal of Diabetes and its Complications
Volume32
Issue number12
Pages (from-to)1113-1117
Number of pages5
ISSN1056-8727
DOIs
Publication statusPublished - 1 Dec 2018

ID: 55457135